Legal & General Group Plc held its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 25,685 shares of the biotechnology company’s stock at the end of the 2nd quarter. Legal & General Group Plc’s holdings in ImmunoGen were worth $184,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Aperio Group LLC increased its stake in ImmunoGen by 45.1% during the second quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock valued at $119,000 after purchasing an additional 5,221 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in ImmunoGen by 2.8% during the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock valued at $107,000 after purchasing an additional 743 shares during the last quarter. Trexquant Investment LP bought a new stake in ImmunoGen during the second quarter valued at $232,000. Parametric Portfolio Associates LLC increased its stake in ImmunoGen by 7.7% during the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 2,753 shares during the last quarter. Finally, Stephens Inc. AR bought a new stake in ImmunoGen during the first quarter valued at $152,000. Hedge funds and other institutional investors own 65.66% of the company’s stock.
IMGN has been the subject of several recent research reports. Cowen and Company reiterated a “hold” rating on shares of ImmunoGen in a research note on Tuesday, August 29th. William Blair reiterated an “outperform” rating on shares of ImmunoGen in a research note on Monday, June 26th. BidaskClub lowered shares of ImmunoGen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. Cantor Fitzgerald set a $5.00 price target on shares of ImmunoGen and gave the stock a “hold” rating in a research report on Friday, July 28th. Finally, Jefferies Group LLC restated a “buy” rating and set a $6.00 price target on shares of ImmunoGen in a research report on Wednesday, June 28th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company’s stock. ImmunoGen currently has an average rating of “Hold” and an average price target of $8.05.
ILLEGAL ACTIVITY NOTICE: “Legal & General Group Plc Has $184,000 Position in ImmunoGen, Inc. (IMGN)” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/10/14/legal-general-group-plc-has-184000-position-in-immunogen-inc-imgn.html.
In other ImmunoGen news, VP Craig Barrows sold 14,600 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total transaction of $101,470.00. Following the completion of the transaction, the vice president now directly owns 51,100 shares in the company, valued at $355,145. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.51% of the company’s stock.
ImmunoGen, Inc. (NASDAQ:IMGN) opened at 5.97 on Friday. The stock’s 50 day moving average is $7.11 and its 200 day moving average is $5.66. The company’s market cap is $534.89 million. ImmunoGen, Inc. has a 52-week low of $1.51 and a 52-week high of $8.84.
ImmunoGen (NASDAQ:IMGN) last released its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.07. The company had revenue of $39.02 million for the quarter, compared to analyst estimates of $30.59 million. During the same quarter in the prior year, the company earned ($0.53) earnings per share. The business’s revenue was up 426.6% compared to the same quarter last year. On average, analysts predict that ImmunoGen, Inc. will post ($0.73) earnings per share for the current fiscal year.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Want to see what other hedge funds are holding IMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunoGen, Inc. (NASDAQ:IMGN).
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.